70772  pET Expression System 25b plus Competent Cells

pET vectors plus host strains with induction control

This product has been discontinued.

pET Expression Systems and pET
pET Expression Systems and pET Expression Systems plus Competent Cells provide core reagents needed for target gene cloning and expression.

Components: pET Expression Systems
Components for pET Expression Systems are similar for all systems unless otherwise stated with the specific pET Expression System description. pET Expression Systems include:
• 10 µg pET vector DNA (for each indicated plasmid)
• 0.2 ml BL21 Glycerol Stock
• 0.2 ml BL21(DE3) Glycerol Stock
• 0.2 ml BL21(DE3)pLysS Glycerol Stock
• 0.2 ml Induction Control Glycerol Stock

Components: pET Expression Systems plus Competent Cells
pET Expression Systems plus Competent Cells contain all of the components of the specific pET Expression System, as well as the following additional components, unless otherwise stated with the specific pET Expression System description:
• 0.2 ml NovaBlue Competent Cells
• 0.2 ml BL21(DE3) Competent Cells
• 0.2 ml BL21(DE3)pLysS Competent Cells
• 2 × 0.2 ml SOC Medium
• 10 µl Test Plasmid

These components are sufficient for up to 10 transformations in each host.

Purification and Detection Reagents
Purification and detection reagents are available separately. For complete product descriptions and ordering information, refer to the Protein Purification and Antibodies, Conjugates & Detection Tools chapters.

pET Expression System 25b plus Competent Cells
The pET-25b(+) vector carries an N-terminal pelB signal sequence for potential periplasmic localization, plus optional C-terminal HSV•Tag^® and His•Tag^® sequence. Note that the sequence is numbered by the pBR322 convention, so the T7 expression region is reversed on the vector map, TB065VM.

This product is covered under license from Brookhaven National Labs. Commercial entities need to obtain a research use license prior to purchase. Please contact your licensing department to confirm that your company already holds a research use license.